Labcorp Holdings (LH) | Financial Analysis & Statements
Labcorp Holdings Inc. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
3.5B
Gross Profit
993.2M
28.25%
Operating Income
382.0M
10.87%
Net Income
164.9M
4.69%
EPS (Diluted)
$1.98
Balance Sheet Metrics
Total Assets
18.4B
Total Liabilities
9.8B
Shareholders Equity
8.6B
Debt to Equity
1.13
Cash Flow Metrics
Operating Cash Flow
758.9M
Free Cash Flow
490.3M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Labcorp Holdings Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 14.0B | 13.0B | 12.2B | 11.9B | 13.1B |
| Cost of Goods Sold | 9.9B | 9.4B | 8.8B | 8.2B | 8.1B |
| Gross Profit | 4.0B | 3.6B | 3.4B | 3.7B | 5.0B |
| Gross Margin % | 28.8% | 27.9% | 27.7% | 31.3% | 38.0% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 2.2B | 2.2B | 2.0B | 1.8B | 1.7B |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 2.2B | 2.2B | 2.0B | 1.8B | 1.7B |
| Operating Income | 1.5B | 1.1B | 1.1B | 1.8B | 3.1B |
| Operating Margin % | 10.9% | 8.7% | 9.2% | 14.8% | 23.4% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | 224.1M | 208.3M | 199.6M | 179.8M | 211.8M |
| Other Non-Operating Income | -184.6M | 29.8M | -355.2M | -335.0M | 26.8M |
| Pre-tax Income | 1.1B | 959.5M | 568.9M | 1.2B | 2.9B |
| Income Tax | 229.8M | 212.4M | 188.5M | 233.9M | 690.0M |
| Effective Tax Rate % | 20.7% | 22.1% | 33.1% | 18.9% | 23.9% |
| Net Income | 877.7M | 747.1M | 419.2M | 1.3B | 2.4B |
| Net Margin % | 6.3% | 5.7% | 3.4% | 10.8% | 18.1% |
| Key Metrics | |||||
| EBITDA | 2.1B | 1.8B | 1.7B | 2.3B | 3.7B |
| EPS (Basic) | $10.54 | $8.89 | $4.80 | $14.05 | $24.60 |
| EPS (Diluted) | $10.46 | $8.84 | $4.77 | $13.97 | $24.39 |
| Basic Shares Outstanding | 83200000 | 83900000 | 87100000 | 91100000 | 96700000 |
| Diluted Shares Outstanding | 83200000 | 83900000 | 87100000 | 91100000 | 96700000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Labcorp Holdings Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 532.3M | 1.5B | 536.8M | 320.6M | 1.5B |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 2.1B | 1.9B | 1.9B | 1.8B | 2.3B |
| Inventory | 534.7M | 493.2M | 474.6M | 470.6M | 401.4M |
| Other Current Assets | 692.8M | 697.6M | 655.3M | 610.4M | 478.1M |
| Total Current Assets | 4.0B | 4.8B | 3.8B | 4.6B | 5.3B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 803.9M | 784.5M | 737.1M | 738.1M | 746.3M |
| Goodwill | 17.2B | 16.2B | 15.6B | 15.4B | 19.7B |
| Intangible Assets | 3.6B | 3.5B | 3.3B | 3.1B | 3.7B |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 751.3M | 652.2M | 536.5M | 3.4B | 484.2M |
| Total Non-Current Assets | 14.4B | 13.6B | 13.0B | 15.5B | 15.1B |
| Total Assets | 18.4B | 18.4B | 16.7B | 20.2B | 20.4B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 840.8M | 875.8M | 827.5M | 852.2M | 621.3M |
| Short-term Debt | 695.8M | 1.2B | 1.2B | 471.1M | 199.0M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | 657.6M | - |
| Total Current Liabilities | 2.8B | 3.3B | 3.2B | 3.1B | 2.8B |
| Non-Current Liabilities | |||||
| Long-term Debt | 5.8B | 6.1B | 4.8B | 5.8B | 6.1B |
| Deferred Tax Liabilities | 454.5M | 383.1M | 417.9M | 543.4M | 762.9M |
| Other Non-Current Liabilities | 112.1M | 136.2M | 142.3M | 161.3M | 81.1M |
| Total Non-Current Liabilities | 6.9B | 7.0B | 5.6B | 7.0B | 7.3B |
| Total Liabilities | 9.8B | 10.3B | 8.8B | 10.0B | 10.1B |
| Equity | |||||
| Common Stock | 7.5M | 7.6M | 7.7M | 8.1M | 8.5M |
| Retained Earnings | 8.6B | 8.3B | 7.9B | 10.6B | 10.5B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 8.6B | 8.1B | 7.9B | 10.1B | 10.3B |
| Key Metrics | |||||
| Total Debt | 6.5B | 7.3B | 6.0B | 6.2B | 6.3B |
| Working Capital | 1.2B | 1.5B | 540.2M | 1.5B | 2.5B |
Balance Sheet Composition
Labcorp Holdings Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 877.7M | 747.1M | 380.4M | 1.0B | 2.2B |
| Depreciation & Amortization | 681.1M | 643.5M | 577.3M | 537.2M | 577.0M |
| Stock-Based Compensation | 125.8M | 116.7M | 128.7M | 116.8M | 132.9M |
| Working Capital Changes | -170.6M | 13.0M | -12.9M | 330.8M | 227.6M |
| Operating Cash Flow | 2.0B | 1.7B | 1.2B | 2.2B | 3.2B |
| Investing Activities | |||||
| Capital Expenditures | - | - | - | - | - |
| Acquisitions | -575.1M | -823.9M | -671.5M | -1.2B | -496.9M |
| Investment Purchases | -192.4M | -55.0M | -29.0M | -17.4M | -27.8M |
| Investment Sales | - | 0 | 6.7M | 8.1M | 13.2M |
| Investing Cash Flow | -759.5M | -876.9M | -693.2M | -1.2B | -424.2M |
| Financing Activities | |||||
| Share Repurchases | -450.0M | -250.1M | -1.0B | -1.1B | -1.7B |
| Dividends Paid | -240.7M | -243.1M | -254.0M | -195.2M | 0 |
| Debt Issuance | 64.8M | 4.5B | 2.5B | 787.4M | 1.0B |
| Debt Repayment | -1.1B | -3.5B | -2.8B | -787.4M | -1.4B |
| Financing Cash Flow | -1.5B | 723.7M | -1.6B | -534.8M | -2.1B |
| Free Cash Flow | 1.2B | 1.1B | 874.1M | 1.5B | 2.7B |
| Net Change in Cash | -279.1M | 1.6B | -1.0B | 505.0M | 737.7M |
Cash Flow Trend
Labcorp Holdings Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
25.30
Forward P/E
13.74
Price to Book
2.53
Price to Sales
1.56
PEG Ratio
1.55
Profitability Ratios
Profit Margin
6.28%
Operating Margin
10.55%
Return on Equity
10.51%
Return on Assets
5.12%
Financial Health
Current Ratio
1.42
Debt to Equity
75.56
Beta
0.98
Per Share Data
EPS (TTM)
$10.47
Book Value per Share
$104.86
Revenue per Share
$167.69
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| LH | 21.8B | 25.30 | 2.53 | 10.51% | 6.28% | 75.56 |
| Thermo Fisher | 174.6B | 25.84 | 3.31 | 13.52% | 15.15% | 82.91 |
| Danaher | 126.4B | 34.61 | 2.40 | 7.08% | 14.89% | 37.17 |
| Idexx Laboratories | 44.7B | 42.92 | 27.85 | 66.20% | 24.62% | 60.83 |
| Agilent Technologies | 32.7B | 25.67 | 4.76 | 19.95% | 18.26% | 51.39 |
| Waters | 30.5B | 28.90 | 7.24 | 29.28% | 20.30% | 60.28 |
Financial data is updated regularly. All figures are in the company's reporting currency.






